<DOC>
	<DOC>NCT02118337</DOC>
	<brief_summary>To evaluate the safety, tolerability and antitumor activity of MEDI0680 (AMP-514) given in combination with MEDI4736 and MEDI0680 monotherapy.</brief_summary>
	<brief_title>A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With MEDI4736 and MEDI0680 Monotherapy in Subjects With Select Advanced Malignancies</brief_title>
	<detailed_description>This is a multicenter, open-label, dose-escalation, and dose expansion study of MEDI0680 given alone and in combination with MEDI4736 to evaluate the safety, tolerability, pharmacokinetic (PK), immunogenicity, and antitumor activity in adult subjects with select advanced malignancies.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Must be 18 years or older Eastern Cooperative Oncology Group performance status of 01 Adequate organ function No more than 1 prior line of therapy Concurrent enrollment in another clinical study, unless in followup period or it is an observational study Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment Prior treatment with immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>select advanced malignancies</keyword>
</DOC>